Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60075
Name estrogen-receptor positive breast cancer
Definition A breast cancer that is characterized by the presence of estrogen receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer estrogen-receptor positive breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Dovitinib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Cediranib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Nintedanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 amp Brivanib estrogen-receptor positive breast cancer no benefit detail...
ERBB2 act mut Vistusertib estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA E545K AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA K111N AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant AZD8835 estrogen-receptor positive breast cancer sensitive detail...
PIK3CA mutant Fulvestrant + Pictilisib estrogen-receptor positive breast cancer no benefit detail...
PIK3CA mutant Fulvestrant estrogen-receptor positive breast cancer no benefit detail...
PIK3CA act mut Capivasertib + Tamoxifen estrogen-receptor positive breast cancer predicted - sensitive detail...
Unknown unknown Everolimus estrogen-receptor positive breast cancer not applicable detail...
Unknown unknown Everolimus + Tamoxifen estrogen-receptor positive breast cancer not applicable detail...
FGFR1 amp E7090 estrogen-receptor positive breast cancer sensitive detail...
Unknown unknown RO6839921 estrogen-receptor positive breast cancer not applicable detail...
PIK3CA E78K PIK3CA E726K PIK3CA D939G Alpelisib + Letrozole estrogen-receptor positive breast cancer no benefit detail...
FGFR1 amp Alpelisib estrogen-receptor positive breast cancer resistant detail...
FGFR1 amp Lucitanib estrogen-receptor positive breast cancer sensitive detail...
FGFR1 over exp PIK3CA mut Alpelisib + Lucitanib estrogen-receptor positive breast cancer sensitive detail...
RB1 loss Palbociclib estrogen-receptor positive breast cancer resistant detail...
PIK3CA P447_L455del Alpelisib + Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
PIK3CA mutant Letrozole estrogen-receptor positive breast cancer predicted - sensitive detail...
AKT1 E17K Capivasertib estrogen-receptor positive breast cancer predicted - sensitive detail...
RB1 mutant Palbociclib estrogen-receptor positive breast cancer predicted - resistant detail...
PIK3CA H1047R Everolimus estrogen-receptor positive breast cancer predicted - sensitive detail...
ERBB2 over exp Pyrotinib estrogen-receptor positive breast cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Completed
NCT00759642 Phase II Lapatinib Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Terminated
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01219699 Phase I Alpelisib Alpelisib + Fulvestrant A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Completed
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed
NCT01594216 Phase II Exemestane + Ruxolitinib Ruxolitinib in Estrogen Receptor Positive Breast Cancer Completed
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Active, not recruiting
NCT02049957 Phase Ib/II Fulvestrant + Sapanisertib Exemestane + Sapanisertib Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Completed
NCT02115282 Phase III Exemestane + Goserelin Entinostat + Exemestane + Goserelin Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting
NCT02219789 Phase I Fulvestrant Alisertib Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Completed
NCT02229084 Phase Ib/II Montanide ISA 51 + P10s-PADRE P10s-PADRE Vaccination of High Risk Breast Cancer Patients Enrolling by invitation
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed
NCT02340221 Phase III Fulvestrant + Taselisib Fulvestrant A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) Active, not recruiting
NCT02395627 Phase II Pembrolizumab + Tamoxifen + Vorinostat Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification Terminated
NCT02569801 Phase II GDC-0810 Fulvestrant A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy Terminated
NCT02580448 Phase Ib/II VT-464 A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed
NCT02598557 Phase II Exemestane Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer Active, not recruiting
NCT02599714 Phase Ib/II Fulvestrant + Palbociclib + Vistusertib Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) Active, not recruiting
NCT02676986 Phase II Enzalutamide + Exemestane Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Active, not recruiting
NCT02734615 Phase I Alpelisib + LSZ 102 LSZ 102 + Ribociclib LSZ 102 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Active, not recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Recruiting
NCT02820961 Phase I Entinostat + Exemestane Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Unknown status
NCT02913430 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen Phase II Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib Recruiting
NCT02988986 Phase II Sapanisertib + Tamoxifen TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Completed
NCT03092635 Phase I Metformin + OPC AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy Active, not recruiting
NCT03201913 Phase I TTC-352 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy Active, not recruiting
NCT03250676 Phase Ib/II H3B-6545 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Active, not recruiting
NCT03285412 Phase II Ribociclib CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER) Active, not recruiting
NCT03289039 Phase II Neratinib Fulvestrant + Neratinib Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Active, not recruiting
NCT03321981 Phase II Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer Active, not recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting
NCT03361800 Phase I Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Active, not recruiting
NCT03366844 Phase I Pembrolizumab Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation Recruiting
NCT03573648 Phase II Avelumab + Palbociclib + Tamoxifen Avelumab + Tamoxifen Neoadjuvant Tamoxifen, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT) Recruiting
NCT03584009 Phase II Fulvestrant Fulvestrant + Venetoclax A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy Active, not recruiting
NCT03874325 Phase II Durvalumab + Exemestane Durvalumab + Letrozole Anastrozole + Durvalumab Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer Recruiting
NCT04054752 Phase I NT-I7 Vaccine Response With NT-I7 Not yet recruiting
NCT04109066 Phase III Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) Recruiting
NCT04190056 Phase II Pembrolizumab + Tamoxifen Pembrolizumab + Tamoxifen + Vorinostat Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Not yet recruiting
NCT04197999 Phase I GMI-1359 A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Recruiting
NCT04256941 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Recruiting
NCT04305834 Phase II Abemaciclib Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer Recruiting